Retatrutide, by Soma Pharmaceuticals , represents a exciting breakthrough in metabolic regulation. This dual-action medication combines GLP-1 signaling function with GIP receptor agonist activation , indicating impressive potential in trial findings for metabolic loss . Scientists believe Retatrutide is expected to represent a different option for